Phase Ib/II evaluation of RAD001 with docetaxel and bevacizumab in patients with metastatic androgen independent prostate cancer
Phase of Trial: Phase I/II
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Everolimus (Primary) ; Bevacizumab; Docetaxel
- Indications Prostate cancer
- Focus Adverse reactions
- 09 Apr 2017 Status changed from active, no longer recruiting to completed.
- 26 Oct 2015 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
- 26 Oct 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.